Microcap Ledger Advanced Biomed Inc. $ADVB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Services-Medical Laboratories
- Headquarters
- Reno, NV
- Fiscal year end
- June 30
- Shares outstanding
- 1,382,133 [10-Q 2026-05-15]
What the company doesAI summary of filing
Advanced Biomed Inc. develops microfluidic-based medical devices and in vitro diagnostic products for early cancer detection and analysis, primarily focused on circulating tumor cell (CTC) detection in blood samples. The company's products include automated systems (A+ Pre, AC-1000, A+ CellScan, A+ SCDrop), microfluidic biochips, immunostaining kits, and a 3D cell culture platform (A+PerfusC). The company is currently pre-revenue; two products (A+ Pre and AC-1000) have received regulatory clearance from China's NMPA and can be mass-produced, while other products are in registration application or review stages. Advanced Biomed manufactures through subsidiaries in Taiwan and China, with plans to expand into North America and Europe, and expects continuous losses for the next two to three years pending completion of clinical development and regulatory approvals. [10-K 2025-10-08]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 9 months to Mar 2026 | — | $5.98M | −$1.36M | $2.60M | [10-Q 2026-05-15] |
| FY ended Jun 2025 | — | −$3.26M | −$5.83M | $2.87M | [10-K 2025-10-08] |
| FY ended Jun 2024 | — | −$2.78M | −$2.13M | $2.61M | [10-K 2025-10-08] |
- Quarterly cash burn
- −$454.6K
- Cash runway Estimate
- ~17.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-31 | 21,640,000 | [10-Q 2025-05-15] |
| 2025-10-08 | 21,640,000 | [10-K 2025-10-08] |
| 2025-11-19 | 21,640,000 | [10-Q 2025-11-19] |
| 2025-12-31 | 21,640,000 | [10-Q 2026-02-13] |
| 2026-03-31 | 1,382,133 | [10-Q 2026-05-15] |
- Shelf registration
- S-1 filed 2025-07-23; no effectiveness notice found in EDGAR [S-1 2025-07-23]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-01-21. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-01-21 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-21] |
| 2025-07-24 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-07-24] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-27 | Pau Hung To | other | 100,000 | $480000.00 | [4 2026-08-20] |
| 2026-07-27 | Pau Hung To | other | 76,225 | $480000.00 | [4 2026-08-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | NT 10-K | Notice of late annual report |
| 2026-09-22 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-20 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-20 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-17 | 8-K | Material agreement terminated |
| 2026-07-01 | 8-K | Shareholder vote results |
| 2026-06-30 | 8-K | Material agreement entered |
| 2026-06-04 | DEF 14A | Proxy statement |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-01 | 8-K | Acquisition or disposition completed; Unregistered sale of equity; Director or officer change |
| 2026-04-14 | 8-K | Material agreement entered |
| 2026-04-03 | 8-K | Material agreement entered |
Alerts for $ADVB
Email me when Advanced Biomed Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.